Spermosens announces advancements in second-generation JUNO-Checked system

Spermosens AB ("Spermosens" or the "Company") is pleased to share additional information on the enhanced capabilities of its second-generation JUNO-Checked system, a significant advancement in male fertility diagnostics. JUNO-Checked is the first device that enables clinicians and researchers to measure sperm binding capacity - a critical parameter that complements current analyses in IVF clinics and provides deeper insights into male fertility.

The second-generation JUNO-Checked system builds on the strengths of the initial platform, introducing enhancements in sensitivity, accuracy and data processing speed. These improvements are tailored to increase the device's utility in clinical settings and strengthen its role in the ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö.

Key achievements of the second-generation JUNO-Checked system:

• Enhanced Sensitivity and Accuracy: The upgraded sensor technology in the second generation delivers more precise measurements of sperm binding ability, a capability unique to JUNO-Checked. This advancement reduces noise and variability, which is crucial for identifying subtle variations that may be linked to IVF success.
• Faster data processing: The system’s advanced biosensors enable more rapid and robust data analysis, allowing for complex statistical evaluations. This improvement is particularly valuable in clinical use, where multiple parameters are analyzed together to establish JUNO-Checked’s diagnostic value.
• Ease of use: The new JUNO-Checked system features a more user-friendly design, making it easier for lab teams to operate and ensuring data collection remains consistent across samples. This enhanced usability is especially advantageous for laboratories handling large sample volumes.
• Increased sample throughput: The upgraded JUNO-Checked system also supports higher sample throughput, allowing for faster processing of more samples. This capability is particularly beneficial for fertility clinics looking to streamline operations.

Tore Duvold, CEO of Spermosens, comments: “I’m proud of what our team has achieved with the second-generation JUNO-Checked system. This latest version reflects our deep commitment to addressing key challenges in male fertility diagnostics. By enhancing sensitivity, accuracy and efficiency, we’re equipping fertility specialists with more reliable insights that truly support their work. These advancements allow us to better serve clinical partners and bring real value to an area that impacts so many lives.”

These technical advancements bring Spermosens closer to fulfilling its mission of addressing critical gaps in male fertility diagnostics, offering specialists innovative tools that support more effective fertility treatments.

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com